combination insulin glp 1 Frontiers Main physiological actions of the

In the SOD1 G93A mouse model of ALS, pyruvate (1000 mg/kg/week i.p.) slowed disease progression and also improved motor symptoms in a rotarod test and survival by 10.5% when it was administered starting at the onset of disease (Park et al., 2007)

A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism

10.1371/journal.pone.0131394 122

Most users experience balanced, manageable results when therapy is properly monitored

Without continued diet and exercise, most users experience some regain

Ji D, Chen Y, Bi J, Shang Q, Liu H, Wang JB, Tan L, Wang J, Chen Y, Li Q, Long Q, Song L, Jiang L, Xiao G, Yu Z, Chen L, Wang X, Chen D, Li Z, Dong Z, Yang Y